MBI Proven to be Equivalent to MRI in the Detection of Breast Cancer

December 13, 2011Molecular breast imaging (MBI) has been found to be equivalent to magnetic resonance imaging (MRI) as an adjunct imaging modality in the diagnosis of breast cancer. MBI may be especially useful for the evaluation of high-risk women or those with dense breasts.

According to the study authors, MRI has become increasingly popular as an adjunct to mammography in the diagnosis of breast cancer. Despite its sensitivity in lesion detection, MRI is expensive and can cause patient discomfort. MBI has similar sensitivity to MRI, costs less and is comfortable for the patient. This study aimed to directly compare the two modalities.

It was concluded that MBI results led to further workup and detection of occult malignancies. In fact, negative MRIs without contradictory MBI results would have led to six missed malignant tumors in this study. Also, the authors noted that as the study demonstrated MBI’s equivalency to MRI in the diagnosis of breast cancer, that MBI may be useful for the evaluation of high-risk women or those with dense breasts. For this study MBI was conducted with a high-resolution gamma camera, the Dilon 6800.

Beyond demonstrating that MBI is equivalent to MRI in the diagnoses of breast cancer, Nathalie Johnson, M.D., chief breast surgeon at Legacy Good Samaritan Hospital in Portland, Ore., and author on this study, said, “Its application may be particularly relevant for evaluation of newly diagnosed breast cancer to rule out additional disease with a lower false positive rate.” Additional researchers on the study were Esther Han, M.D. and Margie Glissmeyer in Portland, Ore.

As a follow-up to mammography, MBI utilizes the Dilon 6800 gamma camera to help physicians more clearly differentiate benign from malignant tissue. To perform MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal healthy cells and generally appear as dark spots on the MBI image.

For more information: www.dilon.com


Related Content

Feature | Breast Imaging

Despite decades of progress in breast imaging, one challenge continues to test even the most skilled radiologists ...

Time October 24, 2025
arrow
News | Radiology Imaging | UC San Diego Health

Oct. 16, 2025 — A strategic collaboration between UC San Diego Health and GE HealthCare will focus on bringing advanced ...

Time October 20, 2025
arrow
News | RSNA 2025

Oct. 7, 2025 – Clairity Inc., a leader in AI-based breast cancer risk prediction, will make five scientific ...

Time October 07, 2025
arrow
News | Mammography | Mayo Clinic

Early detection is key to breast cancer survival. But nearly half of all women in the U.S. have dense breast tissue ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...

Time September 18, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 11, 2025 — A new PET tracer can provide insights into how spinal cord injuries affect not only the spinal cord ...

Time September 12, 2025
arrow
News | Mammography

Sept. 3, 2025 — According to ARRS’ American Journal of Roentgenology (AJR), a commercial artificial intelligence (AI) ...

Time September 09, 2025
arrow
News | Mammography

Aug. 19, 2025 — According to the latest study from BCC Research, the "Global Mammography Equipment Markets" is projected ...

Time August 20, 2025
arrow
News | Mammography

Aug. 19, 2025 — Calidar, Inc., a start-up in precision diagnostic imaging formed out of Duke University, recently ...

Time August 19, 2025
arrow
News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
Subscribe Now